AIDSVAX® (MN) in Bangkok injecting drag users: A report on safety and immunogenicity, including macrophage-tropic virus neutralization

AIDS Research and Human Retroviruses

Volumn 16, Issue 7, 2000, Pages 655-663

  Migasena, Sricharoen ^a   Suntharasamai, Pravan ^a   Pitisuttithum, Punnee ^a   Kitayaporn, Dwip ^a   Wasi, Chantapong ^b   Huang, Wei ^c   Vanichseni, Suphak ^d   Koompong, Charnchai ^d   Kaewkungwal, Jaranit ^a   Raktham, Suwanee ^d   Ippolito, Tina ^e   Hanson, Carl ^f   Gregory, Timothy ^c   Heyward, William L ^g,h   Berman, Phillip ^e   Francis, Donald P ^e  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c GENENTECH INC   (United States)

^d Bangkok Metropolitan Administration   (Thailand)

^e VaxGen Inc   (United States)

^f CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^g WORLD HEALTH ORGANIZATION   (Switzerland)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIGEN P24; CD4 ANTIGEN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; HIV ENVELOPE PROTEIN GP120 (305 321); HIV ENVELOPE PROTEIN GP120 (305-321); PEPTIDE FRAGMENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ERYTHEMA; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION PAIN; INTRAVENOUS DRUG ABUSE; MACROPHAGE; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VIRUS NEUTRALIZATION; BLOOD; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOLOGY; PHYSIOLOGY; SERODIAGNOSIS; SUBSTANCE ABUSE; THAILAND; VIROLOGY;

AIDS VACCINES; DOUBLE-BLIND METHOD; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION SCHEDULE; MACROPHAGES; MALE; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; SUBSTANCE ABUSE, INTRAVENOUS; THAILAND; VACCINATION;

EID: 0034178248     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200308882     Document Type: Article

References (26)

1. 1. Weniger BG, Limpakarnjanarat K, Ungchusak K, et al.: The epidemiology of HIV infection and AIDS in Thailand. AIDS 1991;5(Suppl. 2):S71-S85.
2. 2. Choopanya K, Yanichseni S, Des Jarlais DC, et al.: Risk factors and HIV seropositivity among injecting drug users in Bangkok. AIDS 1991;5:1509-1513.
3. 3. Des Jarlais DC, Choopanya K, Vanichseni S, et al.: AIDS risk reduction and reduced HIV seroconversion among injection drug users in Bangkok. Am J Public Health 1994;84:452-455.
4. 4. Ministry of Public Health: AIDS surveillance report, Thailand. Wkly Epidemiol Surveill Rep (Thailand) 1993;24(2):13-29.
5. 5. Kitayaporn D, Uneklabh C, Weniger BG, et al.: HIV-1 incidence determined retrospectively among drug users in Bangkok, Thailand. AIDS 1994;8:1443-1450.
6. 6. Ou CY, Takebe Y, Weniger BG, et al.: Independent introduction of two major HIV-1 genotypes into distinct high-risk populations in Thailand. Lancet 1993;341(8854):1171-1174. [Published erratum in Lancet 1993;342(8865):250]
7. 7. Pau CP, Lee-Thomas S, Auwanit W, et al.: Highly specific V3 peptide enzyme immunoassay for serotyping HIV-1 specimens in Thailand. AIDS 1993;7:337-340.
8. 8. Weniger BG, Takebe Y, Ou CY, and Yamazaki S: The molecular epidemiology of HIV in Asia. AIDS 1994;8(Suppl. 2):S13-S28.
9. 9. Wasi C, Herring B, Raktham S, et al.: Determination of HIV-1 subtypes in injecting drug users in Bangkok, Thailand, using peptide-binding enzyme immunoassay and heteroduplex mobility assay: Evidence of increasing infection with HIV-1 subtype E. AIDS 1995;9:843-849.
10. 10. Kalish ML, Baldwin A, Raktham S, et al.: The evolving molecular epidemiology of HIV-1 envelope subtypes in injecting drug users in Bangkok, Thailand: Implications for HIV vaccine trials. AIDS 1995;9:851-857.
11. 11. Esparza J, Osmanov S, Kallings L, and Wigzell H: Planning for HIV vaccine trials: The World Health Organization perspective. AIDS 1991;5(Suppl. 2):S159-S163.
12. 12. Kitayaporn D, Vanichseni S, Mastro TD, et al.: HIV-1 incidence, subtypes, and follow-up in a prospective cohort of injecting drug users (IDUs) in Bangkok, Thailand. In: XIIth World AIDS Conference, Geneva, Switzerland, 1998. [Abstract 13127]
13. 13. Berman PW, Gregory TJ, Riddle L, et al.: Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature (London) 1990; 345:622-625.
14. 14. Berman PW, Murthy KK, Wrin T, et al.: Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type I. J Infect Dis 1996;173:52-59.
15. 15. Belshe RB, Graham BS, Keefer MC, et al.: Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 1994;272: 475-480.
16. 16. Mastro TD, Kitayaporn D, Weniger BG, et al.: Estimating the number of HIV-infected injection drug users in Bangkok, Thailand: A capture-recapture method. Am J Public Health 1994;84:1094-1099.
17. 17. Berman PW, Gray AM, Wrin T, et al.: Genetic and immunologic characterization of viruses infecting MN-rgp120 vaccinated volunteers. J Infect Dis 1997;176:384-397.
18. 18. Hanson CV, Crawford-Miksza L, and Sheppard HW: Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers. J Clin Microbiol 1990;28:2030-2034.
19. 19. Wrin J, Loh TP, Vennari JC, Schuitemaker H, and Nunberg JH: Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J Virol 1995;69:39-48.
20. 20. Moore JP, Cao Y, Leu J, Qin L, Korber B, and Ho DD: Inter and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic subtypes. J Virol 1996;70: 427-444.
21. 21. Pang S, Vinters HV, Akashi T, O'Brien WA, and Chen ISY: HIV-1 envelope sequence variation in brain tissue of patients with AIDS-related neurologic disease. J Acquir Immune Defic Syndr 1991; 4:1082-1092.
22. 22. D'Souza MP, Livnat D, Bradac JA, and Bridges SH: Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials. J Infect Dis 1997;175:1056-1062.
23. 23. Cohen J: U.S. panel votes to delay real-world vaccine trials. Science 1994;264:1839.
24. 24. Francis DP, Gregory T, McElrath MJ, et al.: Advancing AIDSVAX™ to phase III. Safety, immunogenicity, and plans for phase III. AIDS Res Hum Retroviruses 1998;14:S325-S331.
25. 25. Clements-Mann ML: Lessons for AIDS vaccine development from non-AIDS vaccines. AIDS Res Hum Retroviruses 1998;14: S197-S203.
26. 26. Berman PW: Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res Hum Retroviruses 1998;14: S277-S289.